Camenor Competitors

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

At Daiichi Sankyo, we believe progress depends on asking more of science. We are 20,000 people across 30 countries, united by the courage to challenge assumptions and pursue better answers. Across oncology and beyond, we develop new medicines and new approaches to discovery and delivery, addressing unmet medical needs and bringing treatment options within reach. Since 1899, curiosity, rigor and perseverance have shaped how we work. Behind every treatment is a person, a family and a future. That human purpose drives us to keep learning, questioning and advancing science for patients around the world. For more information, please visit www.daiichisankyo.com See our community guidelines here: https://www.daiichisankyo.com/community_guidelines/index.html

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. We are dedicated to capturing the scientific opportunities of our time. With our early roots in Sweden, we started as pioneers in haemophilia. Today we are an innovative leader within rare diseases with a global reach. Together we are bringing brilliant ideas to life. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.